Men's Health Boston, Brookline, Massachusetts, and New York Medical College (JZ), Valhalla, New York.
J Urol. 2014 Apr;191(4):1072-6. doi: 10.1016/j.juro.2013.10.070. Epub 2013 Oct 23.
Testosterone deficiency is a known risk factor for osteopenia and osteoporosis in older men. Less is known about the impact of testosterone deficiency on bone mineral density in younger men.
We retrospectively reviewed the charts at an andrology/infertility clinic and identified 399 men younger than 50 years who underwent baseline dual energy x-ray absorptiometry and had total testosterone less than 350 ng/dl or free testosterone less than 1.5 ng/dl. Additional analysis was done in a subgroup of 75 men (18.8%) in whom dual energy x-ray absorptiometry was repeated after treatment at a mean ± SD of 30.4 ± 16.2 months. The determination of osteoporosis or osteopenia was based on T-scores (osteopenia less than -1.0 and osteoporosis less than -2.5) of the lumbar spine and left hip.
Of all 399 men 141 (35.3%) had bone mineral density consistent with osteopenia at the lumbar spine (137) and/or the total hip (19). In 11 men (2.75%) bone mineral density was consistent with osteoporosis at the lumbar spine. On multivariate analysis higher body mass index was independently associated with increased bone mineral density at the spine (p <0.0001) as well as the hip (p <0.001). Testosterone treatment in 43 men increased spine bone mineral density (p <0.001). Significant decreases in spine bone mineral density developed in 21 men treated with clomiphene citrate or anastrazole (p = 0.003). No significant change was noted in hip bone mineral density for any treatment.
More than a third of men younger than 50 years with testosterone deficiency and infertility or sexual dysfunction had decreased bone mineral density. Testosterone treatment increased bone mineral density while estrogen modulators such as clomiphene citrate or aromatase inhibitors decreased bone mineral density. These results suggest that dual energy x-ray absorptiometry may be warranted in young men with testosterone deficiency.
睾酮缺乏是导致老年男性骨量减少和骨质疏松的已知危险因素。对于睾酮缺乏对年轻男性骨密度的影响了解较少。
我们回顾了一家男科/不孕不育诊所的病历,并确定了 399 名年龄小于 50 岁的男性,他们在基线时进行了双能 X 射线吸收法检查,且总睾酮水平低于 350ng/dl 或游离睾酮水平低于 1.5ng/dl。对其中 75 名男性(18.8%)的亚组进行了进一步分析,这些男性在平均 30.4±16.2 个月后接受了双能 X 射线吸收法检查。骨质疏松症或骨量减少的确定基于腰椎和左侧髋部的 T 评分(骨量减少<-1.0 和骨质疏松<-2.5)。
在所有 399 名男性中,141 名(35.3%)的腰椎(137 名)和/或全髋部(19 名)的骨密度符合骨量减少的标准。在 11 名男性(2.75%)中,腰椎的骨密度符合骨质疏松症的标准。多变量分析显示,较高的体重指数与腰椎(p<0.0001)和髋部(p<0.001)的骨密度增加独立相关。43 名男性接受睾酮治疗后腰椎骨密度增加(p<0.001)。接受克罗米酚或阿那曲唑治疗的 21 名男性腰椎骨密度显著下降(p=0.003)。任何治疗对髋部骨密度均无显著变化。
超过三分之一的因不育或性功能障碍而出现睾酮缺乏和不孕的年轻男性骨密度降低。睾酮治疗可增加骨密度,而克罗米酚或芳香化酶抑制剂等雌激素调节剂则可降低骨密度。这些结果表明,对于睾酮缺乏的年轻男性,可能需要进行双能 X 射线吸收法检查。